RxDoctor Payments Data

Arlene Keller, MD

Internal Medicine · San Francisco, CANPI 1740392885

Payments from drug & device makers

$309in general payments, 2019–2025

Across 8 payments — averaging $38.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$175
  • Amarin Pharma, Inc.$50
  • Johnson & Johnson$39
  • Gilead$25
  • Pfizer$21

What the payments were for

  • Consulting fees$17557%
  • Food & beverage$13443%

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen1$175
Amarin Pharma, Inc.3$50
Johnson & Johnson2$39
Gilead1$25
Pfizer1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$309 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$221,137
Medicare patients
501
Services billed
1,922

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$77,025
EliquisApixaban72$73,134
JardianceEmpagliflozin36$59,441
JanuviaSitagliptin Phosphate34$54,327
XareltoRivaroxaban25$30,588
ArexvyRsvpref3 Antigen/As01e/Pf86$26,695
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr32$18,528
Atorvastatin Calcium1,046$11,733
ShingrixVaricella-Zoster Ge/As01b/Pf53$11,661
Breo ElliptaFluticasone/Vilanterol16$10,963
Wixela InhubFluticasone Propion/Salmeterol26$6,018
Levothyroxine Sodium402$6,005
Losartan Potassium504$5,580
SymbicortBudesonide/Formoterol Fumarate11$5,371
Boostrix TdapDiphth,pertuss(Acell),tet Vac76$5,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$73,13472 claims
Johnson & JohnsonXarelto$39$30,58825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →